In breast cancer, low expression of DARPP‐32 was associated with adverse patient survival9; in colorectal cancer and glioblastoma multiforme, high expression of DARPP‐32 was associated with adverse survival.8, 32. This evidence concerns the gene PPP1R1B and colorectal cancer.